TORONTO, March 23 /CNW/ - Dalton Medicinal Chemistry Partners, the
Medicinal Chemistry arm of Dalton Pharma Services, announces the signing of a
Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd.
Dalton Medicinal Chemistry Partners will utilize their medicinal
chemistry expertise to design and synthesize novel compounds against a number
of antiviral targets selected by Boehringer Ingelheim (Canada) Ltd.
Peter Pekos, President of Dalton Pharma Services, said: "We are pleased
to enter this exciting partnership with Boehringer Ingelheim (Canada) Ltd by
bringing the added value of our medicinal chemistry capabilities and expertise
to their antiviral research projects."
About Dalton Pharma Services
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health
Canada approved contract pharmaceutical manufacturer that supplies chemistry,
medicinal chemistry and analytical services to the biotechnology and
pharmaceutical industries in the areas of chemistry, medicinal chemistry, fine
chemical manufacture, custom peptides and antisense oligo production. Dalton
provides cGMP manufacturing and sterile filling services to its customers at
any stage of the regulatory process (Phase I, II, III or commercial). In its
state of the art cGMP facilities, Dalton can produce active pharmaceutical
ingredients (API), at the gram or kilogram scale. Dalton can carry out sterile
fills to produce batches of finished drug product in vials or syringes, either
aseptically filled or terminally sterilized, under fully validated conditions.
In addition, Dalton's analytical chemistry laboratory offers method
development, validation and ICH stability programs to its clients.
For further information:
For further information: Dalton Pharma Services, Peter Pekos, (416)